Gilead
 
Tiered Pricing

More Information

For regional questions, please contact International Access Operations by e-mail or phone.

Email:
Access@gilead.com

Telephone:
+1-650-522-5101

In developing countries, Gilead's branded products are priced using a tiered system that reflects each country's ability to pay. The tiers, which are evaluated on an ongoing basis, are based primarily on a country's gross national income per capita and its HIV prevalence. Product prices in the wealthiest nations are based on the product's full value, and substantial discounts are given in low- and lower middle-income tiers.

  • Low Income Pricing Tier: In this tier, Truvada® and Viread® are available at $26.25 and $17 per month, respectively. These ex-factory prices are based on Gilead's cost of goods and production volumes. Based on current manufacturing costs and other operating costs in these markets, our expenses exceed our revenues in this tier.
    Countries in this tier

  • Lower Middle Income Pricing Tier: Truvada and Viread are available at $45 and $30 per month, respectively.
    Countries in this tier

  • Upper Middle Income Pricing Tier: Prices in these countries represent as much as a 70 percent discount relative to high-income regions of the world.
    Countries in this tier